Venture capital firms High-Tech Gründerfonds and Born2Grow invest in Preventicus GmbH
October 6, 2014
Preventicus GmbH is developing smartphone-driven solutions to capture and analyze patients’ vital parameters for early preclinical risk screening of lifestyle-related illnesses. Seed funding for the Jena-based company is managed by the German High-Tech Gründerfonds (HTGF) in Bonn and Born2Grow venture fund in Heilbronn. The capital is being provided to develop the products and portal to marketability.
It is the mission of Preventicus to help make a significant contribution to preventing lifestyle-related illnesses or diseases of Western civilization, such as heart attacks, strokes or burn-out syndromes, by means of early detection in preclinical settings and thus lower the high mortality rates associated with these diseases. Statistically, up to 30 percent of victims do not survive their myocardial infarction, for example. The capture and analysis of patients’ vital parameters via smartphones opens up previously unimagined diagnostic possibilities and scopes.
By recording pulse curves with cameras and flashes and applying biosignal analysis methods, among others, to pulse wave analysis and heart rate variability, the team at Preventicus has succeeded in generating valid evidence regarding clinical pictures like hypertension and vascular stiffness, coronary artery disease, atrial fibrillation, but also on stress and burn-out syndromes. “This type of detection can be done so early that it lets us prevent morbidity or even lethal events (such as an infarction) before clinical symptoms are manifest and/or enable treatments to be implemented with greater promise,” states Dr. Thomas Hübner, founder and managing director of Preventicus GmbH.
The products will be marketed through a web portal and diagnostic apps. “We see a great opportunity in this technology and in the strategy of making these products accessible to the end-users and B2B customers and thereby making occupational healthcare management in the cardiology sector, among others, validly measureable,” add Mr. Victor, fund manager at Born2Grow.
The suppliers of wearables and manufacturers of sports and leisure devices that measure vital biometric data are already servicing a multi-billion Euro global market with double-digit annual growth rates. “The trend here is clearly obvious: these suppliers want to garner the preventive medicine sector for themselves. By investing in Preventicus, we aim to offer prevention-oriented solutions for this market,” explains Marco Winzer, Investment Director at HTGF.
Preventicus is actively evolving a portal and app products, while in parallel planning their rollout for the latter half of 2015.
About Preventicus GmbH
The company is headquartered in Jena, Germany and was founded in May 2014. The team possesses a high level of expertise based on decades of experience in global front-running pioneering research in the field of the pulse wave analysis and heart rate variability. The complex signal analysis algorithms for detecting various clinical pictures have been developed and validated in clinical trials.
Dr. Thomas Hübner
07745 Jena, Germany
BORN2GROW is a completely privately-held German Venture Capital Fund founded in the beginning of 2013. With the initial investment of up €500,000, early stage companies can develop their products up to market maturity and deliver a proof of concept. The funds focus is to invest in high tech technologies within various industries such as IT, Automation, Life Science, Med Tech and Telecommunication. Enterprises do not only get the financial support of BORN2GROW but also gain strategic knowledge throughout the funds extensive entrepreneurial-driven network.
About High-Tech Gründerfonds
High-Tech Gründerfonds invests venture capital in young technology companies with promising research results and strong potential to enable then to transform innovative ideas into entrepreneurial success. Seed financing helps startups take their R&D projects to the prototype, “proof-of-concept” or market launch phases. The fund participates with an initial €500,000; a total of up to €2 million per enterprise are available. The public-private partnership investors include the German Federal Ministry of Economics and Technology, the KfW Banking Group alongside the 18 corporate investors ALTANA, BASF, Bayer, B. Braun, Robert Bosch, CEWE Color, Daimler, Deutsche Post DHL, Deutsche Telekom, Evonik, Lanxess, media + more venture Beteiligung, METRO, Qiagen, RWE Innogy, SAP, Tengelmann and Carl Zeiss. High-Tech Gründerfonds manages a total investment portfolio of around €576 million (€272m Fonds I and €304m Fonds II).